Toridip 20 – selection antagonists of calcium with primary action on vessels, for treatment of essential hypertensia of light or moderate severity.

Structure

• active ingredient: lercanidipine hydrochloride;
• 1 tablet, film coated, contains a hydrochloride of a lerkanidipin 20 mg;
• other components: corn starch, krakhmalglikolit sodium (type A), silicon dioxide colloidal anhydrous, cellulose microcrystalline, the sodium stearylfumarating povidone, a gipromeloza, polyethyleneglycol 6000, ferrous oxide red (E 172.

Contraindication

Hypersensitivity to active ingredient, other dihydropyridines or to any component of drug. Contraindicated to women of reproductive age if they do not apply contraception. Obstruction of the vessels leaving a left ventricle. Not treated stagnant heart failure. Unstable stenocardia. Heavy abnormal liver functions or kidneys (for Toridip 20). Contraindicated within 1 month after a myocardial infarction. Simultaneous use with strong CYP inhibitors 3A4, cyclosporine and juice of grapefruit.

Side reactions

from the immune system: hypersensitivity.

from mentality: drowsiness.

from nervous system: headache, dizziness.

from a cardiovascular system: stenocardia, tachycardia, the strengthened heartbeat, hyperaemia, a faint.

from a digestive tract: nausea, pain in epigastriums, diarrhea, dyspepsia, vomiting.

from skin: rash.

from a musculoskeletal system: myalgia.

from an urinary system: polyuria.

General disturbances: peripheral hypostases, asthenia, fatigue.

Route of administration

Recommended dose for adults makes 10 mg (for what use the medicament Toridip 10) 1 time a day, not less than in 15 minutes prior to food; the dose can be raised to 20 mg (applying Toridip 20) depending on individual sensitivity of the patient. The dosage is established gradually as the maximum antihypertensive action can be shown in 2 weeks after an initiation of treatment.

Toridip 20 can be accepted along with inhibitors of angiotensin-converting enzyme (APF), diuretic means, β-adrenoblockers. It is improbable that the efficiency of medicament will increase with increase in its dosage, but, at the same time, increase in undesirable effects is possible.

Feature of use

Use during pregnancy or feeding by a breast

Use of a lerkanidipin during pregnancy or feeding by a breast contraindicated.

Use of a lerkanidipin is not recommended to children by

as there is no clinical experience.

Ability to influence speed of response at control of motor transport or other mechanisms

Clinical experience of use of a lerkanidipin shows that deterioration in ability to run motor transport or it is improbable to work with other mechanisms, but it is necessary to be careful as can arise dizziness, an asthenia, fatigue and drowsiness.

messages about three cases of overdose caused by suicide attempt Were p>

.

Also, as well as in case of other dihydropyridines, could expect

that the overdose will lead to an excessive peripheral vazodilatation with noticeable arterial hypotension and reflex tachycardia. In case of heavy arterial hypotension, bradycardia or a loss of consciousness it is necessary to apply intravenous administration of atropine. Considering the prolonged pharmacological action of a lerkanidipin, patients with overdose need to be under observation of the doctor within 24 hours. Information on assessment of dialysis is absent. As lerkanidipin vysokolipofilen, it is the most probable that its concentration in blood plasma is not the parameter reflecting risk period duration, and dialysis can be inefficient.

Interaction with other medicines and other types of interactions

It is known that lerkanidipin is metabolized under the influence of CYP enzyme 3A4 and therefore the inhibitors and inductors of this enzyme accepting along with lerkanidipiny can influence process of metabolism and elimination. Interaction of a lerkanidipin with such CYP inhibitors 3A4 as ketokonazol, itrakonazol, ritonavir, erythromycin, troleandomitsin it is necessary to avoid as at the same time concentration of a lerkanidipin in blood plasma considerably increases (15-fold increase in value of the area under a curve-times increase in the maximum average value of concentration for an eutomer (S-lerkanidipina).

Cyclosporine and lerkanidipin cannot be applied at the same time as at the same time there is an increase in concentration in blood plasma. At use of cyclosporine during 3 h after reception of a lerkanidipin the concentration of a lerkanidipin in blood plasma does not change while the AUC value for cyclosporine increases by 27%. However simultaneous use of a lerkanidipin and cyclosporine leads to increase in concentration of a lerkanidipin in blood plasma by 3 times, and the AUC value of cyclosporine increases by 21%.

with grapefruit juice. As well as all others of dihydropyridine lerkanidipin it is especially sensitive to juice of grapefruit, which slows down his metabolism that increases its bioavailability and increases antihypertensive action.

to Store

at a temperature not over 25 With in original packing.

to Store

out of children's reach.